Continuous glucose monitoring systems (CGMS) are real time, portable glucose monitoring systems used for the measurement of glucose levels at regular intervals from the patient’s body. These devices use wireless technology for transmitting glucose readings collected from the interstitial fluid between the patient’s skin cells, unlike blood glucose meters that measure glucose levels in the blood. According to International Diabetes Federation (IDF), approximately 382 million people were diagnosed with diabetes globally in 2013 and this number is expected to grow to 592 million by 2035. Similarly, in the U.K. approximately 10% of the total diabetic population are diagnosed with type I diabetes. Additionally, according to JDRF the prevalence of type I diabetes rose by 23% in the U.S. between 2001 and 2009 for children under 20 years of age. Thus, CGMS are identified as one of the most important emerging tools for diabetes management, especially type I diabetes in which patients are completely insulin dependent.
This report on continuous glucose monitoring studies the current scenario as well as the future market potential for continuous glucose monitoring systems (CGMS) globally. The market for these continuous glucose monitoring systems (CGMS) has been segmented by major devices/brands, namely, Guardian Real Time CGM System, FreeStyle Navigator, Dexcom Seven Plus CGM System, Dexcom G4 Platinum, MiniMed Paradigm Revel/Veo System and others. The continuous glucose monitoring systems market for these systems has been extensively analyzed on the basis of factors such as their commercial launch, sales revenue, geographic presence, usage and technological developments. The market size and forecasts in terms of revenue (USD million) for each of above mentioned segments have been provided for the period 2011 to 2019, considering 2012 as the base year. The report also provides the compounded annual growth rate (CAGR) for each segment for the forecast period 2013 to 2019.
Geographically, the continuous glucose monitoring market has been classified into four segments namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecast for each region has been provided for the period 2011 to 2019 along with the CAGR (%) for the forecast period 2013 to 2019. The study also includes qualitative analysis of the competitive scenario in these regions. The market overview section of the report comprises qualitative analysis of the overall market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter’s five force analysis and market attractiveness analysis. Porter’s five forces analysis would help determine the degree of competition among the players and the threat from new entrant or substitutes. Furthermore, the report on CGM also includes executive summary, that that will help you understand the overall market size, growth rate of various segments, geographies and competitors present in the market in a very precise manner.
The report on CGM also provides a section on the competitive landscape, wherein the market share analysis of leading players in the global continuous glucose monitoring market (CGM), in terms of percentage share in 2012 has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market shares. The continuous glucose monitoring market report concludes with the profiles of major players in the global continuous glucose monitoring market such as Medtronic, Inc., Dexcom, Inc., Abbott Laboratories, Inc., Bayer AG, Nova Biomedical Corporation, Senseonics, Incorporated, GlySens, Incorporated and Insulet Corporation. The profiles of these players has been extensively analyzed on the basis of product portfolio, company overview, financial overview, recent developments and business strategies adopted by the companies to ensure sustainability and maximize profits.